Effects of metalloproteinase inhibition in a murine model of renal ischemia-reperfusion injury

Pediatric Research

Volumn 67, Issue 3, 2010, Pages 257-262

  Novak, Katherine B ^a   Le, Hau D ^a   Christison Lagay, Emily R ^a   Nose, Vania ^b   Doiron, Robert J ^a   Moses, Marsha A ^a   Puder, Mark ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; GELATINASE A; MARIMASTAT; METHYLCELLULOSE;

ACUTE KIDNEY TUBULE NECROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOSE RESPONSE; DRUG ACTIVITY; DRUG DOSE COMPARISON; ENZYME ACTIVITY; ENZYME INHIBITION; KIDNEY INJURY; KIDNEY ISCHEMIA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY;

ANIMALS; BIOLOGICAL MARKERS; BLOTTING, WESTERN; CREATININE; DISEASE MODELS, ANIMAL; HYDROXAMIC ACIDS; KIDNEY; KIDNEY TUBULAR NECROSIS, ACUTE; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED C57BL; PROTEASE INHIBITORS; REPERFUSION INJURY; SEVERITY OF ILLNESS INDEX;

EID: 76749109833     PISSN: 00313998     EISSN: 15300447     Source Type: Journal    
DOI: 10.1203/PDR.0b013e3181ca0aa2     Document Type: Article

References (50)

1. Shoskes DA, Halloran PF 1996 Delayed graft function in renal transplantation: etiology, management and long-term significance. J Urol 155:1831-1840
2. Paul LC 1995 Chronic renal transplant loss. Kidney Int 47:1491-1499
3. Azuma H, Nadeau K, Takada M, Mackenzie HS, Tilney NL 1997 Cellular and molecular predictors of chronic renal dysfunction after initial ischemia/reperfusion injury of a single kidney. Transplantation 64:190-197
4. Star RA 1998 Treatment of acute renal failure. Kidney Int 54:1817-1831
5. Kelly KJ, Molitoris BA 2000 Acute renal failure in the new millennium: time to consider combination therapy. Semin Nephrol 20:4-19
6. Bonventre JV, Weinberg JM 2003 Recent advances in the pathophysiology of ischemic acute renal failure. J Am Soc Nephrol 14:2199-2210
7. Padanilam BJ 2003 Cell death induced by acute renal injury: a perspective on the contributions of apoptosis and necrosis. Am J Physiol Renal Physiol 284:F608-F627
8. Bonventre JV, Zuk A 2004 Ischemic acute renal failure: an inflammatory disease? Kidney Int 66:480-485
9. Donnahoo KK, Shames BD, Harken AH, Meldrum DR 1999 Review article: the role of tumor necrosis factor in renal ischemia-reperfusion injury. J Urol 162:196-203
10. Roy R, Zhang B, Moses MA 2006 Making the cut: protease-mediated regulation of angiogenesis. Exp Cell Res 312:608-622
11. Lenz O, Elliot SJ, Stetler-Stevenson WG 2000 Matrix metalloproteinases in renal development and disease. J Am Soc Nephrol 11:574-581
12. Bonventre JV 1993 Mechanisms of ischemic acute renal failure. Kidney Int 43:1160-1178
13. Sutton TA, Molitoris BA 1998 Mechanisms of cellular injury in ischemic acute renal failure. Semin Nephrol 18:490-497
14. Donnahoo KK, Meng X, Ayala A, Cain MP, Harken AH, Meldrum DR 1999 Early kidney TNF-alpha expression mediates neutrophil infiltration and injury after renal ischemia-reperfusion. Am J Physiol 277:R922-R929
15. Donnahoo KK, Meldrum DR, Shenkar R, Chung CS, Abraham E, Harken AH 2000 Early renal ischemia, with or without reperfusion, activates NFkappaB and increases TNF-alpha bioactivity in the kidney. J Urol 163:1328-1332
16. Moss ML, Jin SL, Milla ME, Bickett DM, Burkhart W, Carter HL, Chen WJ, Clay WC, Didsbury JR, Hassler D, Hoffman CR, Kost TA, Lambert MH, Leesnitzer MA, McCauley P, McGeehan G, Mitchell J, Moyer M, Pahel G, Rocque W, Overton LK, Schoenen F, Seaton T, Su JL, Warner J, Willard D, Becherer JD 1997 Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature 385:733-736
17. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, Castner BJ, Stocking KL, Reddy P, Srinivasan S, Nelson N, Boiani N, Schooley KA, Gerhart M, Davis R, Fitzner JN, Johnson RS, Paxton RJ, March CJ, Cerretti DP 1997 A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 385:729-733
18. Bramhall SR, Hallissey MT, Whiting J, Scholefield J, Tierney G, Stuart RC, Hawkins RE, McCulloch P, Maughan T, Brown PD, Baillet M, Fielding JW 2002 Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. Br J Cancer 86:1864-1870
19. Rosenbaum E, Zahurak M, Sinibaldi V, Carducci MA, Pili R, Laufer M, DeWeese TL, Eisenberger MA 2005 Marimastat in the treatment of patients with biochemically relapsed prostate cancer: a prospective randomized, double-blind, phase I/II trial. Clin Cancer Res 11:4437-4443
20. Alwayn IP, Andersson C, Lee S, Arsenault DA, Bistrian BR, Gura KM, Nose V, Zauscher B, Moses M, Puder M 2006 Inhibition of matrix metalloproteinases increases PPAR-alpha and IL-6 and prevents dietary-induced hepatic steatosis and injury in a murine model. Am J Physiol Gastrointest Liver Physiol 291:G1011-G1019
21. Rasmussen HS, McCann PP 1997 Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. Pharmacol Ther 75:69-75
22. Tsuji F, Oki K, Okahara A, Suhara H, Yamanouchi T, Sasano M, Mita S, Horiuchi M 2002 Differential effects between marimastat, a TNF-alpha converting enzyme inhibitor, and anti-TNF-alpha antibody on murine models for sepsis and arthritis. Cytokine 17:294-300
23. Weight SC, Furness PN, Nicholson ML 1998 New model of renal warm ischaemia-reperfusion injury for comparative functional, morphological and pathophysiological studies. Br J Surg 85:1669-1673
24. McWhinnie DL, Thompson JF, Taylor HM, Chapman JR, Bolton EM, Carter NP, Wood RF, Morris PJ 1986 Morphometric analysis of cellular infiltration assessed by monoclonal antibody labeling in sequential human renal allograft biopsies. Transplantation 42:352-358
25. Solez K, Racusen LC, Marcussen N, Slatnik I, Keown P, Burdick JF, Olsen S 1993 Morphology of ischemic acute renal failure, normal function, and cyclosporine toxicity in cyclosporine-treated renal allograft recipients. Kidney Int 43:1058-1067
26. Moses MA, Wiederschain D, Loughlin KR, Zurakowski D, Lamb CC, Freeman MR 1998 Increased incidence of matrix metalloproteinases in urine of cancer patients. Cancer Res 58:1395-1399
27. Camphausen K, Moses MA, Beecken WD, Khan MK, Folkman J, O'Reilly MS 2001 Radiation therapy to a primary tumor accelerates metastatic growth in mice. Cancer Res 61:2207-2211
28. Chan LW, Moses MA, Goley E, Sproull M, Muanza T, Coleman CN, Figg WD, Albert PS, Menard C, Camphausen K 2004 Urinary VEGF and MMP levels as predictive markers of 1-year progression-free survival in cancer patients treated with radiation therapy: a longitudinal study of protein kinetics throughout tumor progression and therapy. J Clin Oncol 22:499-506
29. Reponen P, Sahlberg C, Huhtala P, Hurskainen T, Thesleff I, Tryggvason K 1992 Molecular cloning of murine 72-kDa type IV collagenase and its expression during mouse development. J Biol Chem 267:7856-7862
30. Winn RK, Ramamoorthy C, Vedder NB, Sharar SR, Harlan JM 1997 Leukocyte-endothelial cell interactions in ischemia-reperfusion injury. Ann N Y Acad Sci 832:311-321
31. Roberts IS, Brenchley PE 2000 Mast cells: the forgotten cells of renal fibrosis. J Clin Pathol 53:858-862
32. Yamada M, Ueda M, Naruko T, Tanabe S, Han YS, Ikura Y, Ogami M, Takai S, Miyazaki M 2001 Mast cell chymase expression and mast cell phenotypes in human rejected kidneys. Kidney Int 59:1374-1381
33. Matsumoto H, Koga H, Iida M, Tarumi K, Fujita M, Haruma K 2006 Blockade of tumor necrosis factor-alpha-converting enzyme improves experimental small intestinal damage by decreasing matrix metalloproteinase-3 production in rats. Scand J Gastroenterol 41:1320-1329
34. Bergers G, Javaherian K, Lo KM, Folkman J, Hanahan D 1999 Effects of angio-genesis inhibitors on multistage carcinogenesis in mice. Science 284:808-812
35. Lutz J, Yao Y, Song E, Antus B, Hamar P, Liu S, Heemann U 2005 Inhibition of matrix metalloproteinases during chronic allograft nephropathy in rats. Transplantation 79:655-661
36. Bramhall SR, Rosemurgy A, Brown PD, Bowry C, Buckels JA 2001 Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol 19:3447-3455
37. Coussens LM, Fingleton B, Matrisian LM 2002 Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295:2387-2392
38. Gilles S, Zahler S, Welsch U, Sommerhoff CP, Becker BF 2003 Release of TNF-alpha during myocardial reperfusion depends on oxidative stress and is prevented by mast cell stabilizers. Cardiovasc Res 60:608-616
39. Goto T, Ishizaka A, Kobayashi F, Kohno M, Sawafuji M, Tasaka S, Ikeda E, Okada Y, Maruyama I, Kobayashi K 2004 Importance of tumor necrosis factor-alpha cleavage process in post-transplantation lung injury in rats. Am J Respir Crit Care Med 170:1239-1246
40. Tang ZY, Loss G, Carmody I, Cohen AJ 2006 TIMP-3 ameliorates hepatic ischemia/ reperfusion injury through inhibition of tumor necrosis factor-alpha-converting enzyme activity in rats. Transplantation 82:1518-1523
41. Amour A, Slocombe PM, Webster A, Butler M, Knight CG, Smith BJ, Stephens PE, Shelley C, Hutton M, Knauper V, Docherty AJ, Murphy G 1998 TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett 435:39-44
42. Nicotera P, Leist M, Ferrando-May E 1999 Apoptosis and necrosis: different execution of the same death. Biochem Soc Symp 66:69-73
43. Sheridan AM, Bonventre JV 2000 Cell biology and molecular mechanisms of injury in ischemic acute renal failure. Curr Opin Nephrol Hypertens 9:427-434
44. Vetterlein F, Petho A, Schmidt G 1986 Distribution of capillary blood flow in rat kidney during postischemic renal failure. Am J Physiol 251:H510-H519
45. Basile DP, Fredrich K, Weihrauch D, Hattan N, Chilian WM 2004 Angiostatin and matrix metalloprotease expression following ischemic acute renal failure. Am J Physiol Renal Physiol 286:F893-F902
46. Yan L, Borregaard N, Kjeldsen L, Moses MA 2001 The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL. J Biol Chem 276:37258-37265
47. Mishra J, Ma Q, Kelly C, Mitsnefes M, Mori K, Barasch J, Devarajan P 2006 Kidney NGAL is a novel early marker of acute injury following transplantation. Pediatr Nephrol 21:856-863
48. Fine RN, Tejani A 1998 Growth following renal transplantation in children. Transplant Proc 30:1959-1960
49. Guyot C, Karam G, Soulillou JP 1994 Pediatric renal transplantation without maintenance steroids. Transplant Proc 26:97
50. Smith ER, Zurakowski D, Saad A, Scott RM, Moses MA 2008 Urinary biomarkers predict brain tumor presence and response to therapy. Clin Cancer Res 14:2378-2386